FIXX ALERT: Investors Suffering Substantial Losses Have Opportunity to File Class Action Lawsuit Against Homology Medicines, Inc.

SAN DIEGO–(BUSINESS WIRE)–Robbins Geller Rudman & Dowd LLP announces that purchasers of Homology Medicines, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022 inclusive (the “Class Period”) have until May 24, 2022 to seek an appointment as plaintiff main in Pizzuto v Homology Medicines, Inc., no. 22-cv-01968 (CD Cal.). Begun on March 25, 2022 and awarded to Judge Fernando L. Aenlle-Rocha, the Homology drugs The class action accuses Homology Medicines and some of its top executives of violating the Securities Exchange Act of 1934.

If you have suffered significant losses and wish to act as the lead plaintiff of the Homology drugs class action, please provide your information by clicking here. You can also contact attorney JC Sanchez of Robbins Geller by calling 800/449-4900 or emailing [email protected] Principal Applicant’s Requests for Homology drugs the class action must be filed with the court no later than May 24, 2022.

CASE ALLEGATIONS: Homology Medicines is a genetic drug company and its lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (“PKU”) in adults that is in a Phase I/II clinical trial of pheNIX ( the “HMI-102 test”). On June 10, 2019, Homology Medicines issued a press release announcing that it had started recruitment for the HMI-102 trial.

the Homology drugs The class action alleges that, throughout the class period, the defendants made false and misleading statements and failed to disclose that: (i) Homology Medicines overestimated the efficacy and risk mitigation of the HMI -102; (ii) therefore, it was unlikely that Homology Medicines would be able to commercialize HMI-102 in its current form; and (iii) therefore, the public statements of Homology Medicines were materially false and misleading at all relevant times.

On July 21, 2020, Mariner Research released a report questioning the claims of Homology Medicines and its officials about the effectiveness of HMI-102. Mariner focused on Homology Medicines HMI-102 dose escalation pheNIX trial, concluding that Homology Medicines was hiding data showing the lack of efficacy of HMI-102 and indicating that it was unlikely that the program goes to commercialization. Among other evidence, Mariner cited an email from the director of communications at Homology Medicines that appeared to indicate that Homology Medicines knew that a patient on a high dose of HMI-102 had reported the adverse efficacy issue in a social media post. social media in April 2020. On this news, Homology Medicines stock price fell more than 10%.

Then, on February 18, 2022, Homology Medicines revealed that “the United States Food and Drug Administration (FDA) has informed the company that its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria (PKU) has been placed on clinical hold due to the need to modify risk mitigation measures in the study in response to observations of elevated liver function tests” and that Homology Medicines “expects to receive a hold letter official clinical within 30 days.” On this news, Homology Medicines’ stock price fell more than 32%, further hurting investors.

THE PRINCIPAL APPLICANT PROCESS: The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Homology Medicines securities during the class action period to seek appointment as a lead plaintiff in the Homology drugs class action. A principal plaintiff is generally the plaintiff with the greatest financial interest in the remedy sought by the putative class that is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members by directing the class action. The lead plaintiff may select a law firm of their choice to litigate the class action. The ability of an investor to share in any potential future rally in the class legal action does not depend on the status of principal plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: Robbins Geller Rudman & Dowd LLP is one of the world’s leading complex class action firms representing plaintiffs in securities fraud cases. The firm is ranked No. 1 in the 2021 ISS Securities Class Action Services Top 50 report for recovering nearly $2 billion for investors last year alone, more than triple the amount recovered by any other firm from plaintiffs. With 200 attorneys in 9 offices, Robbins Geller attorneys have secured many of the largest securities class action recoveries in history, including the largest securities class action recovery on record – $7.2 billion dollars – in In re Enron Corp. Dry. Litigation Please visit for more information.

Lawyer advertisement.

Past results do not guarantee future results.

Services can be performed by attorneys in any of our offices.

Comments are closed.